Inhibitor Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Inhibitor Therapeutics, Inc. (INTI) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $37.10 thousand as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $37.10K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $34.23K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $34.23K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $34.23K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $37.10K 10-K · filed 2026-03-26 |
| 2024-12-31 | $34.23K 10-K · filed 2026-03-26 |
| 2023-12-31 | $34.23K 10-K · filed 2025-03-28 |
| 2022-12-31 | $34.23K 10-K · filed 2024-03-29 |
| 2021-12-31 | $34.23K 10-K · filed 2023-03-31 |
| 2020-12-31 | $34.23K 10-K · filed 2021-03-26 |
| 2020-12-12 | $34.23K 10-K · filed 2022-03-30 |
| 2019-12-31 | $33.94K 10-K · filed 2021-03-26 |
| 2018-12-31 | $33.94K 10-K · filed 2020-03-30 |
| 2017-12-31 | $9.42K 10-K · filed 2019-03-07 |
| 2016-12-31 | $2.01M 10-K · filed 2018-02-16 |
| 2015-12-31 | $841.52K 10-K · filed 2017-02-17 |
| 2014-12-31 | $256.22K 10-K · filed 2016-02-01 |